NPS Pharmaceuticals, Inc.(NASDAQ:NPSP) announced its support for World Hypoparathyroidism Awareness Day by introducing a free Emergency Resources Kit designed to support accurate and more rapid diagnosis of Hypoparathyroidism symptoms in emergency care and other medical care settings. The annual global observance encourages the public to increase awareness of the disorder and the need for more education, improved diagnosis, and new treatment options. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) stock opened today at $37.18 and is currently trading at $35.18. The stock showed a positive weekly performance of 18.86%.
Global Markets Direct’s, ‘AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Product Pipeline Review – 2014′, provides an overview of the AVEO Pharmaceuticals, Inc.’s pharmaceutical research and development focus. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) stock opened at $1.17, in current trading session and currently is at $1.09, by losing -1.80%. The 52 week range of $1.00 – $2.83. Company’s market capitalization is 56.97 million.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported, for the first time, data from its Phase 2 trial of Iclusig(R) (ponatinib), the company’s approved BCR-ABL inhibitor, in adult patients with refractory metastatic and/or unresectable gastrointestinal stromal tumors (GIST). Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock is currently trading at $6.82. The EPS of the stock is -1.40. Company’s market capitalization is 1.27 billion.
Mylan Inc. (NASDAQ:MYL) today announced that it has entered into a settlement and license agreement with Pfizer Inc. relating to Mylan’s Abbreviated New Drug Application (ANDA) filed with the U.S. Food and Drug Administration (FDA) for Celecoxib Capsules, 50 mg, 100 mg, 200 mg and 400 mg. Mylan Inc. (NASDAQ:MYL) stock opened the session at $49.96, and now is at $49.51. The 52 week range of the Mylan Inc. (NASDAQ:MYL) stock remained $29.50 – $57.52 and the day range was $49.47 – $50.00.
Insurers are looking to partner with doctors to reduce the chance of unnecessary spending. “There are therapies that have high value and there are therapies that may not have much value,” said Lee Newcomer, a senior vice president at UnitedHealth Group Inc. (NYSE:UNH). He noted insurance companies’ motives are viewed with suspicion when it comes to deciding whether a treatment is cost-effective, so having ASCO play a key role in establishing such guidelines would be crucial to their implementation. UnitedHealth Group Inc. (NYSE:UNH) stock opened today at $79.77 and is currently trading at $79.38. The stock showed a positive weekly performance of 1.65%.
Leave a Reply